Survival of Patients with Advanced Non-Small Cell Lung
Cancer at Single Institute in Eastern Thailand, 2013 to 2016
Sitthi Sukauichai MD1
Affiliation :
1 Department of Chemotherapy Unit, Chonburi Cancer Hospital, Chonburi, Thailand
Objective : To study the survival of patient with advanced non-small cell lung carcinoma [NSCLC] treated at Chonburi Cancer
Hospital, in addition to focus on an epidermal growth factor receptor [EGFR] mutation testing, including an epidermal growth
factor receptor-tyrosine kinase inhibitor [EGFR-TKI] therapy and to (cid:976)ind a prognostic factor for survival.
Materials and Methods : The present retrospective cohort study was conducted by review medical records of stage IIIB-IV NSCLC
patients treated at Chemotherapy unit, Chonburi Cancer Hospital, Thailand, between July 1, 2013 and June 30, 2016.
Results : There were 148 patients with median follow-up time 7.90 months. Median age was 60.5 years old (range 25 to 91). There
were male 64%, non-smokers 37%, and stage IIIB/IV 17/83%. The Eastern cooperative oncology group [ECOG] performance status
0 to 1, 2 to 4, and no record were found 35%, 36%, and 29%, respectively. The most common systemic (cid:976)irst-line and second-line
systemic therapies were platinum-based doublet and docetaxel, respectively. The median survival time of all patients was 8.04
months. Median survival times of patients receiving and not receiving systemic therapies were 10.60 months and 3.00 months,
respectively (p<0.001). Less than a quarter of the patients (27/148, 18.2%) were tested for EGFR mutations. Fifty (cid:976)ive percent
(15/27) of the patients tested for EGFR status were sensitive mutations. Unfortunately, only some of them could access to an
EGFR-TKI therapy and mostly received it as a late-line therapy. Multivariate analysis showed that ECOG performance status 2 to
4 (p<0.001), no record for ECOG performance status (p = 0.001), no lung metastasis (p = 0.012), and unknown of EGFR mutation
status (p = 0.001) were signi(cid:976)icantly unfavorable prognostic factors for the survival.
Conclusion : The survival time of advanced NSCLC patients at Chonburi Cancer Hospital was comparable to other pivotal studies.
In real-life clinical practice, EGFR testing was quite low because of limitation to access to EGFR-TKI. The poor ECOG performance
status, no record for ECOG performance status, no lung metastasis and unknown EGFR mutation were poor prognostic factors for
the overall survival.
Keywords : Non-small cell lung cancer, Survival, EGFR mutation, Prognostic factor
All Articles
Download